HC Wainwright Boosts Sana Biotechnology (NASDAQ:SANA) Price Target to $11.00

Sana Biotechnology (NASDAQ:SANA - Get Free Report) had its price objective lifted by HC Wainwright from $8.00 to $11.00 in a report released on Wednesday,Benzinga reports. The firm currently has a "buy" rating on the stock. HC Wainwright's price target suggests a potential upside of 155.81% from the company's current price.

A number of other analysts also recently weighed in on the stock. TD Cowen raised shares of Sana Biotechnology from a "hold" rating to a "buy" rating in a report on Wednesday. JMP Securities lowered shares of Sana Biotechnology from an "outperform" rating to a "market perform" rating in a research report on Tuesday, November 5th. One research analyst has rated the stock with a hold rating and four have given a buy rating to the company's stock. According to data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $14.25.

Sana Biotechnology Stock Performance

Shares of Sana Biotechnology stock traded up $2.65 during trading on Wednesday, reaching $4.30. The company's stock had a trading volume of 160,452,780 shares, compared to its average volume of 38,752,840. Sana Biotechnology has a one year low of $1.52 and a one year high of $12.00. The firm has a market cap of $960.06 million, a price-to-earnings ratio of -3.07 and a beta of 1.45. The business's fifty day moving average price is $2.38 and its 200-day moving average price is $4.07.

Sana Biotechnology (NASDAQ:SANA - Get Free Report) last issued its quarterly earnings results on Friday, November 8th. The company reported ($0.25) EPS for the quarter, topping the consensus estimate of ($0.26) by $0.01. Sell-side analysts anticipate that Sana Biotechnology will post -1.16 EPS for the current year.

Institutional Investors Weigh In On Sana Biotechnology

Institutional investors and hedge funds have recently bought and sold shares of the business. FMR LLC boosted its position in shares of Sana Biotechnology by 16.3% during the 3rd quarter. FMR LLC now owns 31,609,175 shares of the company's stock valued at $131,494,000 after acquiring an additional 4,438,949 shares in the last quarter. Geode Capital Management LLC lifted its stake in Sana Biotechnology by 9.6% during the third quarter. Geode Capital Management LLC now owns 3,166,480 shares of the company's stock worth $13,175,000 after purchasing an additional 276,055 shares during the period. Stifel Financial Corp acquired a new stake in Sana Biotechnology during the third quarter valued at approximately $43,000. Integral Health Asset Management LLC boosted its holdings in Sana Biotechnology by 22.4% during the second quarter. Integral Health Asset Management LLC now owns 1,200,000 shares of the company's stock valued at $6,552,000 after purchasing an additional 220,000 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. grew its stake in shares of Sana Biotechnology by 11.2% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 1,047,846 shares of the company's stock valued at $4,359,000 after purchasing an additional 105,382 shares during the period. Institutional investors own 88.23% of the company's stock.

About Sana Biotechnology

Sana Biotechnology, Inc, a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others.